Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Selecting Therapy for HR+ Breast Cancer

July 26th 2018

The Spectrum of HR+ Breast Cancer: Approaching Treatment

July 26th 2018

Dr. Tripathy on the Importance of Biosimilars in Oncology

July 26th 2018

Debu Tripathy, MD, professor and chairman, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the importance of biosimilars in oncology.

Dr. Murthy on Caveats of the PERSEPHONE Trial in Breast Cancer

July 26th 2018

Rashmi K. Murthy, MD, assistant professor, Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses caveats of the PERSEPHONE trial.

FDA Approves Magnetic Localization System for Lymph Node Biopsy in Breast Cancer

July 25th 2018

The FDA has approved the Magtrace and Sentimag Magnetic Localization System used to guide lymph node biopsies in women undergoing mastectomy for breast cancer.

Dr. Gerber on the Future Landscape of Radiation Oncology

July 25th 2018

Naamit K. Gerber, MD, assistant professor, Department of Radiation Oncology, NYU Langone’s Perlmutter Cancer Center, discusses the future landscape of radiation oncology.

Breast Cancer Meeting in Houston

July 24th 2018

We traveled to Houston, Texas for a State of the Science Summit on Breast Cancer on July 11, 2018. The conference covered radiation therapy, triple-negative breast cancer, BRCA-positive tumors, takeaways from the 2018 ASCO Annual Meeting, and more.

Dr. Arun on Ongoing Research in Triple-Negative Breast Cancer

July 24th 2018

Banu Arun, MD, professor in the Department of Breast Medical Oncology, Division of Cancer Medicine and Department of Clinical Cancer Prevention, Division of OVP, Cancer Prevention and Population Sciences, The University of Texas MD Anderson Cancer Center, discusses ongoing research in triple-negative breast cancer (TNBC).

Dr. Graff on the Use of Sacituzumab Govitecan in Breast Cancer

July 24th 2018

Stephanie L. Graff, MD, director, Breast Program, Sarah Cannon Cancer Institute, associate director, Breast Cancer Research Program, Sarah Cannon Research Institute, discusses the use of sacituzumab govitecan (IMMU-132) in breast cancer.

PIK3CA Remains Elusive in Breast Cancer

July 20th 2018

Researchers remain keenly interested in exploring PIK3CA as an anticancer target in breast cancer.

Future Management of HR+ Metastatic Breast Cancer

July 19th 2018

Role of PI3K Inhibitors in HR+ Metastatic Breast Cancer

July 19th 2018

Role of Everolimus in HR+ Metastatic Breast Cancer

July 19th 2018

Next-Generation Sequencing in HR+ Metastatic Breast Cancer

July 19th 2018

Current Sequencing Approaches in HR+ mBC

July 19th 2018

Role of Fulvestrant Monotherapy in HR+ mBC

July 19th 2018

Optimizing the Use of Endocrine Therapy Partners in mBC

July 19th 2018

MONALEESA-7: Ribociclib in Premenopausal Women With mBC

July 19th 2018

MONALEESA-3: Ribociclib Plus Fulvestrant in HR+ mBC

July 19th 2018

NCCN Guidelines for HR+/HER2- Metastatic Breast Cancer

July 19th 2018